NICE numbers: trends in recommendations should prompt a review of NICE
Should there be a different review of NICE as part of a successor PPRS?
Articles/ Pharma Market Access/ UK & Europe/ Views and analysis
Leela Barham
drug market access, Drug pricing, NICE, pharma market access, Pharmaceutical Price Regulation Scheme, PPRS, UK drug market
0 Comment
Should there be a different review of NICE as part of a successor PPRS?
Articles/ Healthcare/ Pharma Market Access/ UK & Europe/ Views and analysis
Leela Barham
Innovation, Leela Barham, life sciences industrial strategy, Life Sciences Sector Deal, Pharmaceutical Price Regulation Scheme, PPRS
0 Comment
Has the PPRS delivered on the aim to support the government’s growth and innovation agenda?
Articles/ Pharma Market Access/ UK & Europe/ Views and analysis
Leela Barham
drug market access, Leela Barham, market access, medicines assessment, NHS, NHSE, Pharmaceutical Price Regulation Scheme, PPRS
0 Comment
Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
Articles/ Healthcare/ Pharma Market Access/ UK & Europe/ Views and analysis
Leela Barham
Leela Barham, NHS, NHSE, Pharmaceutical Price Regulation Scheme, PPRS
0 Comment
Keeping the UK branded medicines bill within affordable limits – has PPRS delivered?
Articles/ Pharma Market Access/ UK & Europe/ Views and analysis
Leela Barham
Department of Health, DH, Drug pricing, Leela Barham, Pharmaceutical Price Regulation Scheme, PPRS
0 Comment
Has the UK PPRS scheme met its five objectives?